Exemestane in metastatic breast cancer: Effective therapy after third-generation non-steroidal aromatase inhibitor failure
Author:
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference16 articles.
1. Breast cancer with synchronous metastases: trends in survival during a 14-year period;Andre;J Clin Oncol,2004
2. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results;Nabholtz;Eur J Cancer,2003
3. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study;Bonneterre;J Clin Oncol,2000
4. Clinical importance of intratumoral aromatase;Miller;Breast Cancer Res Treat,1998
5. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer;Murray;Breast Cancer Res Treat,1995
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane;Breast Cancer Research and Treatment;2024-04-23
2. Hyper-branched nanodendrimer as a novel solid-phase extraction sorbent followed by three phase hollow fiber microextraction for trace separation of exemestane;Journal of Molecular Liquids;2023-02
3. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin;Breast Cancer Research and Treatment;2021-09-23
4. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane;The Journal of Steroid Biochemistry and Molecular Biology;2020-06
5. The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors;Future Oncology;2019-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3